- Q1 2024 Humacyte Inc Earnings Call TranscriptMay 10, 2024$4.7 (+3.98%)Earnings
- Q4 2023 Humacyte Inc Earnings Call TranscriptMar 22, 2024$3.31 (-8.06%)Earnings
- Q3 2023 Humacyte Inc Earnings Call TranscriptNov 09, 2023$2.21 (+0.91%)Earnings
- Humacyte Inc To Host KOL And Patient Perspectives Event TranscriptSep 20, 2023
- Humacyte Inc Top Line Data Announcement TranscriptSep 12, 2023
- Q2 2023 Humacyte Inc Earnings Call TranscriptAug 14, 2023$4.04 (+23.55%)Earnings
- Q1 2023 Humacyte Inc Earnings Call TranscriptMay 12, 2023$3.97 (-6.48%)Earnings
- Humacyte Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Q4 2022 Humacyte Inc Earnings Call TranscriptMar 24, 2023$2.91 (-5.83%)Earnings
- Humacyte Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Humacyte Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Humacyte Inc At Emerging Growth Conference (Virtual) TranscriptFeb 08, 2023
- Humacyte Inc KOL Webinar: Ukrainian Surgeons Discuss Use of HAV in Wartime TranscriptDec 15, 2022
- Q3 2022 Humacyte Inc Earnings Call TranscriptNov 10, 2022$3.26 (+3.82%)Earnings
- Q4 2021 Humacyte Inc Earnings Call TranscriptMar 29, 2022$6.73 (+5.65%)Earnings
Humacyte Inc At Emerging Growth Conference (Virtual) Transcript
Welcome back, everyone. Next up, we have Humacyte, Inc., and it trades on the NASDAQ under the symbol HUMA. And is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's initial opportunity, a portfolio of human acellular vessels, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for dialysis, and peripheral arterial disease.
Please welcome, its founder and CEO, Dr. Laura Niklason; and CFO, Dale Sander. Welcome. How are you all today?
Thank you very much. We're great. And we really appreciate the opportunity to participate in this forum. I'm very excited to be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)